Treatment of ESBL Urinary Tract Infections

First-Line Treatment Options Based on Severity

The American College of Physicians recommends carbapenems as the first-line treatment for serious ESBL urinary tract infections, while carbapenem-sparing alternatives should be considered for less severe infections to reduce selection pressure for carbapenem resistance 1
Group 2 carbapenems (imipenem/cilastatin, meropenem, doripenem) are preferred for critically ill patients with high bacterial loads or elevated β-lactam MICs 1
Piperacillin/tazobactam may be considered for stable patients with mild to moderate infections, according to the Infectious Diseases Society of America 1, 2
Intravenous fosfomycin has shown high-certainty evidence for treatment of complicated UTIs with or without bacteremia, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 2
Aminoglycosides (including plazomicin) can be effective for cUTI caused by ESBL-producing organisms, but duration should be limited to avoid nephrotoxicity, as suggested by the American College of Clinical Pharmacy 2, 3

Treatment selection should consider local epidemiology of resistance, according to the World Health Organization 4, 1
In areas with high carbapenem-resistant Klebsiella pneumoniae, carbapenem-sparing regimens are strongly recommended, as advised by the Centers for Disease Control and Prevention 5, 4
Fluoroquinolones should be avoided in regions with fluoroquinolone resistance rates >20% among E. coli isolates and should generally be reserved for patients with beta-lactam allergies, as recommended by the European Centre for Disease Prevention and Control 5, 1

Newer agents like ceftolozane/tazobactam and ceftazidime/avibactam should be reserved for multidrug-resistant infections to preserve their activity, according to the Infectious Diseases Society of America 1
Meropenem-vaborbactam and imipenem-cilastatin-relebactam are recommended for complicated UTIs caused by carbapenem-resistant Enterobacteriaceae (CRE), as suggested by the Society of Infectious Diseases Pharmacists 3

Overuse of carbapenems leads to selection pressure and emergence of carbapenem-resistant organisms, as warned by the World Health Organization 1
Extended use of cephalosporins should be discouraged in settings with high incidence of ESBL-producing Enterobacteriaceae, according to the Centers for Disease Control and Prevention 5
Extended use of fluoroquinolones should be discouraged because of selective pressure (mainly for ESBL-producing Enterobacteriaceae), as advised by the European Centre for Disease Prevention and Control 5

For uncomplicated UTIs, short courses (3-5 days) of appropriate antibiotics are sufficient, as recommended by the American College of Physicians 5
For complicated UTIs, treatment duration should be guided by clinical response, with typical courses lasting 7-14 days, according to the Infectious Diseases Society of America 2

Patients should be reassessed when microbiological testing results are available, and antimicrobial de-escalation or withdrawal should be considered when appropriate, as suggested by the Society of Critical Care Medicine 5